Recursion Pharmaceuticals Croissance future

Future contrôle des critères 2/6

Les bénéfices de Recursion Pharmaceuticals devraient diminuer de 1.9% par an tandis que son chiffre d'affaires annuel devrait croître de 23% par an. Le BPA devrait croître de de 10.3% par an. Le rendement des capitaux propres devrait être -168.1% dans 3 ans.

Informations clés

-1.9%

Taux de croissance des bénéfices

10.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices	27.3%
Taux de croissance des recettes	23.0%
Rendement futur des capitaux propres	-168.1%
Couverture par les analystes	Good
Dernière mise à jour	07 Oct 2024

Mises à jour récentes de la croissance future

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Recent updates

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09

We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Mar 01

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:RXRX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	104	-380	-221	-270	5
12/31/2025	63	-465	-365	-337	8
12/31/2024	69	-397	-311	-298	9
6/30/2024	50	-375	-346	-332	N/A
3/31/2024	46	-354	-331	-317	N/A
12/31/2023	45	-328	-300	-288	N/A
9/30/2023	47	-293	-277	-258	N/A
6/30/2023	50	-260	-266	-240	N/A
3/31/2023	47	-249	-273	-234	N/A
12/31/2022	40	-239	-121	-84	N/A
9/30/2022	29	-247	-134	-100	N/A
6/30/2022	18	-234	-113	-78	N/A
3/31/2022	13	-212	-75	-50	N/A
12/31/2021	10	-186	-198	-159	N/A
9/30/2021	10	-147	-129	-89	N/A
6/30/2021	9	-124	-106	-75	N/A
3/31/2021	6	-99	-84	-58	N/A
12/31/2020	4	-87	-52	-45	N/A
12/31/2019	2	-62	-61	-57	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: RXRX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: RXRX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: RXRX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de RXRX ( 23% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de RXRX ( 23% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: RXRX devrait être non rentable dans 3 ans.

Recursion Pharmaceuticals Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Price target decreased by 11% to US$11.57

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Price target decreased by 23% to US$12.33

Consensus EPS estimates fall by 18%

Price target decreased by 10.0% to US$14.86

Recent updates

Recursion Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Co-Founder exercised options and sold US$245k worth of stock

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion: AI Is Only As Good As The Data

Co-Founder exercised options and sold US$244k worth of stock

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. Announces to Appoint David Hallett, Ph.D as Chief Scientific Officer

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Co-Founder notifies of intention to sell stock

Price target decreased by 11% to US$11.57

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 3000E Value Index

Recursion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999995 million.

Recursion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999995 million.

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Co-Founder notifies of intention to sell stock

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Announces Completion of NVIDIA-Powered BioHive-2

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Chief Financial Officer exercised options and sold US$260k worth of stock

Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Co-Founder notifies of intention to sell stock

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Appoints Kristen Rushton as Chief Business Operations Officer

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recursion Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Recursion Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Recursion Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Announces Transition of Shafique Virani from the Chief Business Officer into Senior Strategic Advisor

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Recursion Unveils Lowe Drug Discovery Software At the J.P. Morgan Healthcare Conference

Co-Founder notifies of intention to sell stock

Price target decreased by 23% to US$12.33

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Co-Founder notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$266k worth of stock

Consensus EPS estimates fall by 18%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Announces Completion of Phase 1 Study for Rec-3964 for Clostridioides Difficile Infection

Chief Financial Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Independent Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. announced that it has received $50.000001 million in funding from NVIDIA Corporation

New major risk - Share price stability

Recursion Announces Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation Has Fully Enrolled

Co-Founder & Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Cyclica Inc.

Recursion Pharmaceuticals, Inc. Appoints David Mauro as Chief Medical Officer

Price target decreased by 10.0% to US$14.86

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Valence Discovery for $47.5 million.

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Cyclica Inc. for $40 million.

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Valence Discovery for $47.5 million.

Co-Founder notifies of intention to sell stock